By Judy E. Kim, MD; David Williams, MD, MBA
    ASRS 2013 Annual Meeting

    In this interview from the ASRS 2013 Annual Meeting, Dr. David Williams discusses positive early results from the MAHALO study, which showed that lampalizumab (anti-factor D) can slow the progression rate of geographic atrophy in patients with dry AMD. This is the first study to show a beneficial treatment effect with a complement inhibitor in geographic atrophy.